McKesson Corporation (MCK) continues to attract investor attention due to its consistent performance and strong value. Despite some underperformance compared to competitors and unexpected dips, the company's long-term gains benefit its institutional investors, who own a predominant share of 88%. MCK stock has had notable movement recently thanks to heightened options activity and being deemed as a trending stock. While the quarterly revenue in the U.S. pharmaceutical segment missed estimates, the company exceeded market returns and announced strong momentum. MCK also witnessed an uptrend after the acquisition of Core Ventures and sold its Rexall and Well.ca businesses to Birch Hill Equity Partners. Earnings continue to be a mix bag with EPS soaring; however, revenue missed the mark. McKesson signed an agreement to acquire a controlling interest in Florida Cancer Specialists & Research Institute’s Core Ventures, and their fiscal 2025 first quarter results were announced. Nonetheless, despite a revenue miss, the stock still hit a 52-week high, demonstrating resilience in the face of adversity.
Mckesson Corporation MCK News Analytics from Thu, 04 Jan 2024 08:00:00 GMT to Fri, 20 Sep 2024 21:50:21 GMT -
Rating 0
- Innovation -5
- Information 7
- Rumor -6
